NCT07575880Not yet recruiting
Screening for Obstructive Respiratory Disorders in the General Population During the "Mai Poumon 2026" Prevention Campaign: Prevalence and Impact on the Care Pathway
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 4 May 2026
- Start date
- 9 May 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Centre Hospitalier de la côte Basque
- NCT number
- NCT07575880
What you commit to
- Study type: Observational
- Planned participants: 200
- From 9 May 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion criteria :
- Age ≥ 18 years
- Participating to the prevention campain "Mai Poumons 2026" on 09 Mai 2026
- Exclusion criteria :
- Contre-indication to perform a spirometry : hemoptysy, pneumothorax, myocardal infarction \<1month, thoracic anevrism, recent ophtalmologic, abdominal or thoracic surgery
- Unable to perform a spirometry (understanding, coordination)
- Patient under legal protection
- Patient pregnant or breasting
- Not affiliating to public healthcare
- Patient deprived of liberty
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.